Dr. Farhad Ravandi on How to Treat Minimal Residual Disease

Farhad Ravandi, MD

Farhad Ravandi, MD, Professor in the Department of Leukemia, MD Anderson Cancer Center‎, discusses minimal residual disease. Ravandi says historically, MRD has shown a resistance to cytotoxic chemotherapy.

Farhad Ravandi, MD, Professor in the Department of Leukemia, MD Anderson Cancer Center‎, discusses minimal residual disease (MRD). Ravandi says historically, MRD has shown a resistance to cytotoxic chemotherapy. Furthermore, he says that MRD is an indication that patients are not particularly sensitive to the medication they were given for their leukemia.